Occupational Therapists in Whitefish, MT Accepting Medicare

9 Occupational Therapists found. Showing 1 - 9

Kari Mariah Jurgens, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4780 Whitefish Stage Rd, Whitefish, MT 59937 Phone: 406-863-9204

Gloria Irene Nelson, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 711 E 13th St, Whitefish, MT 59937 Phone: 406-862-9378    Fax: 406-862-9882

Ms. Rebecca Anne Norton, OTR, CHT Occupational Therapist - Hand Medicare: Medicare Enrolled Practice Location: 419 Spokane Ave Apt 1, Whitefish, MT 59937 Phone: 406-862-8175    Fax: 406-862-8176

Handworks Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 419 Spokane Ave Apt 1, Whitefish, MT 59937 Phone: 406-862-8175    Fax: 406-862-8176

Lynnette Fisher, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2006 Hospital Way, Whitefish, MT 59937 Phone: 406-862-9378    Fax: 406-862-9882

Mrs. Patricia A Schnier, OTR Occupational Therapist - Hand Medicare: Not Enrolled in Medicare Practice Location: 6336 Hwy 93 South, Suite 3, Whitefish, MT 59936 Phone: 406-862-8175    Fax: 406-862-1447

Two Bear Therapeutic Riding Center Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1700 K M Ranch Rd, Whitefish, MT 59937 Phone: 406-871-2652

Mrs. Julie Ogle, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1305 E. 7th Street, Genesis Healthcare Whitefish Center, Whitefish, MT 59937 Phone: 406-862-3557

Miss Jillian Rose Nail, OTR Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 533 Somers Ave, Whitefish, MT 59937 Phone: 406-863-2678    Fax: 406-863-2018

News Archive

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

‘Collateral lethality' may create new therapeutic options for several cancers

Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as "collateral lethality," which may create new options for development of therapies for several cancers.

CMS assigns permanent J-code for Savient's KRYSTEXXA to treat RCG

Savient Pharmaceuticals, Inc. today announced that a product-specific billing code, or permanent J-code, for KRYSTEXXA (pegloticase) became available on January 1, 2012.

Abbott presents data from 4 briakinumab pivotal studies in psoriasis

In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874), achieved 75 percent or better skin clearance rates than those treated with etanercept (Enbrel®), methotrexate or placebo. Abbott presented data from all briakinumab pivotal studies in psoriasis at the European Association of Dermatology and Venereology scientific sessions.

Read more Medical News

› Verified 1 days ago